ART Advanced Research Technologies Secures Two Orders for its New Optix MX2 Molecular Imaging System
December 06 2007 - 9:25AM
Marketwired
MONTREAL, QUEBEC (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
that it has received two orders for the recently released
preclinical optical molecular imager, Optix� MX2. The units are
expected to be shipped before the end of the year. This represents
the first Optix units sold by ART under its new commercial
strategy.
"These orders of the Optix MX2 system demonstrate that we are on
track to achieve revenue growth with our new commercialization
strategy under the leadership of Dino DiCamillo, our new global
sales and marketing executive for preclinical imaging," said
Sebastien Gignac, President and CEO of ART.
"ART is building sales momentum with the new team in place and
leveraging internal expertise in optical imaging to offer multiple
solutions to Optix users. In addition to world class products, our
intention is to provide world class service and application
assistance to enable Optix users to fully utilize the potential of
the newly released Optix MX2 and the innovative software solutions
associated to the product in their research programs," concluded
Dino DiCamillo, ART's Vice President, Global Sales & Marketing
for Preclinical Imaging.
About the Optix� system
Based on time-domain technology, which allows measurement of the
light's time of arrival, the Optix� in vivo optical molecular
imaging device is the most sensitive optical imager commercially
available on the precinical market, allowing for detection of lower
concentrations of signals deeper inside the body. Unique to the
Optix system is the ability to recover fluorescence lifetime, which
can be used to separate and quantify probe distributions depending
on their respective biochemical environment. Also part of the Optix
product offering is a new CT fusion software package allowing
researchers to export the scan obtained using Optix in DICOM
format, and fuse it with Micro CT for a full 3D anatomical
reference.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART in North America and Europe
and is used by industry and academic leaders worldwide. The
SoftScan� optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
the SoftScan optical medical imaging device via a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. Finally, the Fenestra� line of molecular imaging contrast
products provide image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in
their imaging studies, with potential extension into other major
imaging modalities. The distribution of the Fenestra line of
imaging contrast agents is made through GE Healthcare Bio-Science
KK in Japan and is sold directly by the Company in the rest of the
world. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer (514) 832-0777 Email: jbedard@art.ca ART
Advanced Research Technologies Inc. Dino DiCamillo, Vice President
Global Sales & Marketing for Preclinical Imaging (514) 832-0777
Email: ddicamil@art.ca Website: www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024